[Decarboxylase inhibitor given in combination with l-dopa. A new therapeutic principal in parkinsonism].
D000284:Administration, Oral; D000818:Animals; D001545:Benserazide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors
D006834:Hydrazines; D004295:Dihydroxyphenylalanine; D001545:Benserazide
Dekarboksylasehemmer gitt i kombinasjon med l-dopa. Et nytt terapeutisk prinsipp ved parkinsonisme.